CEO Executive AssistantBiopharma M&A due diligence is the period in which the CEO of an acquisition target or an acquiring company is expected to operate at maximum intensity across two simultaneous tracks: running the existing business at full performance and leading or managing a due diligence process that is demanding, confidential, and time-constrained. Both tracks are high stakes. Neither can be neglected. And the CEO is typically doing this while managing the anxiety of a leadership team that knows something significant is happening but may not know what.
The time management challenge during M&A due diligence is not about finding more hours. It is about building the decision and delegation architecture that allows both tracks to run in parallel without either one degrading.
The Dual-Track Requirement
When an active M&A process begins, the CEO faces a structural reality: the business does not pause for the deal. Clinical trials continue enrolling. Regulatory submissions move forward. Commercial teams need leadership. Investors expect normal cadence on earnings calls and guidance. And the board is watching both the deal process and the operational performance closely.
At the same time, the due diligence process, whether the company is a target or an acquirer, creates its own intensive demands. Data room preparation, management presentations, cross-functional diligence team coordination, and the CEO’s personal role in answering the questions that only the CEO can answer all require significant time.
CEOs who try to run both tracks personally without structural support fail at one or both. The solution is to define clearly which parts of each track require CEO judgment and to delegate everything else with clear authority.
What Only the CEO Can Own in the Deal Process
On the deal track, the CEO’s non-delegable responsibilities typically include:
Management presentations to the acquiring or target company leadership. These are CEO moments. The CEO’s credibility, strategic vision, and ability to answer hard questions about the business are being assessed directly.
Negotiating or shaping key deal terms. While investment bankers and attorneys handle the mechanics, term decisions that involve strategic commitments, representations about the pipeline, or governance arrangements post-close require CEO involvement.
Communication with the board. Both the deal process and any operational developments during the process require CEO-to-board communication that cannot be delegated.
Regulatory authority engagement. If the deal involves antitrust review or requires FDA communication, the CEO may need to be personally involved in those regulatory relationships.
Everything else in the due diligence process, including data room population, functional-level diligence sessions, financial model support, and document request management, can and should be owned by the CFO, general counsel, and functional leaders.
Running the Business in Parallel
The operational track during M&A is where most CEOs underperform. The deal process is intellectually engaging and feels urgent. The operational track, while equally important, can feel like routine management by comparison. The result is that CEOs drift toward deal activity and away from the operational engagement that keeps the business running well.
The discipline required is the opposite of the instinct. The CEO must deliberately protect operational cadence during the deal process. Canceling the regular leadership team meeting because of a diligence session is a visible signal to the organization that normal business has been subordinated to something else. Even if the leadership team does not know the specifics of what is happening, they read the organizational signals accurately.
Maintaining the Regular Operating Cadence
During an active M&A process, the CEO should maintain the full regular operating cadence: leadership team meetings, one-on-one check-ins with direct reports, board communications, and investor calls. The schedule may be compressed and the CEO may be less available between those anchor meetings, but the anchor meetings should remain intact.
This is not primarily about operational continuity, though that matters. It is about organizational trust. Leadership teams that feel their CEO has become inaccessible and distracted during a significant undisclosed process are more likely to speculate, more likely to engage with recruiters who call, and less likely to be aligned and energized when the deal is announced and their support is needed.
For more on building the executive support infrastructure that allows a CEO to maintain multiple simultaneous commitments, see hiring an executive assistant for pharma CEOs.
Managing Information Compartmentalization
M&A due diligence requires strict information compartmentalization. Not every member of the leadership team will be in the deal circle, particularly in early stages. The CEO is managing relationships with people who may be deeply loyal to the company and yet cannot be told what is happening.
This creates a specific kind of time management stress: the CEO must perform normally in settings where the information asymmetry is significant. Leadership team meetings, external presentations, and investor calls all require the CEO to engage authentically without disclosing material non-public information.
The practical management of this requires preparation. The CEO should know, before any significant meeting during an active process, what can and cannot be discussed. The general counsel and the investment bankers should brief the CEO on any new disclosure sensitivities before each major external event.
The Inner Circle
The CEO’s inner circle during M&A, typically the CFO, general counsel, and occasionally the Chief Business Officer or Chief Scientific Officer, carries an unusual burden. They are managing both their normal responsibilities and the deal process simultaneously, with the same time constraints as the CEO.
The CEO should have an explicit conversation with each inner circle member about workload, capacity, and support needs during the process. This is not a soft management conversation. It is a practical operational investment: inner circle burnout during a deal process produces poor diligence quality, mistakes in legal documents, and relationship damage that outlasts the transaction.
Keeping Key Talent from Defecting
The talent retention challenge during M&A is one of the most underestimated time demands on the CEO. The mechanism is predictable: organizational uncertainty drives engagement from executive recruiters. High-performing leaders who might otherwise be unmoved by a cold call from a search firm are more receptive when they sense significant organizational change is coming, even if they do not know the specifics.
The CEO’s response to this risk is not to disclose the deal earlier than required. It is to invest in targeted relationship maintenance with the critical talent whose loss would be most consequential.
A practical approach is to identify the five to ten leaders who are both most critical to the business and most likely to be attractive to competitors, and to schedule informal CEO conversations with each of them during the deal period. These are not retention conversations; they are relationship maintenance conversations. The CEO should listen more than speak, understand what is engaging and concerning each person, and signal genuine personal investment in their success.
The research on retention through organizational change consistently shows that employees who feel seen and valued by senior leadership are significantly more resilient to external recruitment during uncertainty. The CEO’s personal attention is the highest-value retention tool available.
Harvard Business Review’s analysis of M&A talent dynamics notes that talent departure during the pre-close period is frequently underestimated and that the deals most damaged by talent loss are those where leadership communication was absent rather than present.
Due Diligence Calendar Management
The due diligence calendar, particularly during an intensive sell-side process, can generate a nearly continuous stream of requests, sessions, and management presentations. Without active calendar management, the CEO’s time can be entirely consumed by diligence activity within a week.
The mechanism for preventing this is a clear protocol between the CEO, the deal team lead (typically the CFO or CBO), and the executive assistant. The CEO should establish which diligence sessions require personal attendance, which can be led by functional executives with CEO availability for follow-up questions, and which the CEO should not attend at all.
A useful heuristic: the CEO attends sessions where strategic judgment, pipeline valuation, or organizational capability is being assessed. The CEO does not attend financial model deep dives, data room population sessions, or technical manufacturing diligence unless a specific issue requires CEO presence.
For more on structuring executive time during high-intensity periods, see pharma CEO time management.
Post-Announcement: The New Time Demand
When the deal is announced, the time management challenge shifts. Now the organization knows what is happening, and the CEO must manage a new set of demands: employee all-hands communication, key customer reassurance, investor questions, and integration planning, all while the operational business continues running.
Post-announcement is often the period when CEO bandwidth is most stretched and when the most consequential talent retention decisions must be made quickly. Retention packages, reporting structure clarity, and leadership role definitions all need CEO-level decisions in a compressed window.
The CEO who has maintained operational discipline during the pre-announcement period is far better positioned for this post-announcement sprint. The organizational relationships that sustain trust during uncertainty have been maintained. The operational systems have not been allowed to degrade. The leadership team, even those outside the deal circle, have continued to feel engaged and valued.
M&A due diligence tests whether the CEO has built an organization that can run well without constant CEO intervention. The ones that can do this consistently are the ones where the deal process, however intense, does not disrupt the business that made the deal worth doing.
Related Reading
For further context, explore How Biosimilar Company CEOs Manage Time Across Development and Market Access and How Biotech CEOs Manage Time During IPO Readiness.